Skip to main content

Table 3 Schedule of efficacy assessment/chest CT examination

From: A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

  1. CT computed tomography
  2. Required
  3. ▲ If a patient discontinues the study treatment for a reason other than aggravation of the primary disease, the date when the condition was aggravated is to be identified as much as possible (except for patients who started maintenance treatment). This is not required beyond 548 days after the secondary registration of the last case in this trial
  4. Performed if an adverse event for which a causal relationship with the investigational product cannot be excluded is observed